Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: Analysis in patients from Central and Eastern Europe.

The Journal of dermatological treatment

PubMedID: 28506134

Damjanov N, Karpati S, Kemeny L, Bakos N, Bobic B, Majdan M, Tlustochowicz W, Vitek P, Dokoupilova E, Aldinc E, Szumski A. Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: Analysis in patients from Central and Eastern Europe. J Dermatolog Treat. 2017;1-18.
BACKGROUND
Data are limited on the effectiveness of anti-TNF and other biologics on psoriatric arthritis (PsA) in Central and Eastern Europe (CEE). The objective of this analysis was to evaluate the efficacy of etanercept (ETN) in PsA patients from CEE.

METHODS
In PRESTA, patients were randomised to receive ETN 50?mg BIW or 50?mg QW for 12 weeks (double-blind phase), and ETN 50?mg QW for 12 additional weeks (open-label). In this analysis only patients from Czech Republic, Hungary, Poland, and Serbia were included. The primary efficacy variable was the proportion of subjects achieving a physician global assessment (PGA) of psoriasis status: 'clear' or 'almost clear' at week 12.

RESULTS
In the 307 patients, 54% BIW/QW compared with 40% (QW/QW) (P?=?0.02), achieved 'clear'/'almost clear' for PGA of psoriasis at week 12 increasing, to 68% and 60%, respectively (P?=?0.134) by week 24. Mean improvement from baseline in PASI were 59% vs. 49% (P?=?0.005) at week 6, and 87% vs. 81% (P?
CONCLUSIONS
Both dose regimens of ETN provided significant improvements in efficacy in PsA treatment and were well tolerated.